39927c92-75d7-424c-9bcd-63def0075a1d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.600
- IL6_JAK_STAT3_SIGNALING+0.500
- ALLOGRAFT_REJECTION+0.400
- COMPLEMENT+0.300
- INFLAMMATORY_RESPONSE+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- APICAL_SURFACE+0.200
- APOPTOSIS+0.200
- COAGULATION+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.500
- MYC_TARGETS_V1-0.500
- G2M_CHECKPOINT-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- MITOTIC_SPINDLE-0.300
- MTORC1_SIGNALING-0.300
- PROTEIN_SECRETION-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | e5b29c06-2ed0-4913-bf24-5bfde047defc | — | — | 0.906 |
| 2 | d24acd56-d148-487c-8d44-b303a68eb9d2 | — | — | 0.905 |
| 3 | TCGA-55-8208-01A-11R-2241-07 | — | cohortMD2 | 0.892 |
| 4 | 94b2af92-0cfc-40b2-977d-6bd0fa4440d9 | — | — | 0.887 |
| 5 | TCGA-86-8671-01A-11R-2403-07 | — | cohortMD2 | 0.883 |
| 6 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.879 |
| 7 | TCGA-D8-A73U-01A-11R-A33J-07 | — | D | 0.876 |
| 8 | SRR8613709 | — | A | 0.876 |
| 9 | TCGA-L9-A444-01A-21R-A24H-07 | — | cohortA1 | 0.875 |
| 10 | SRR1430248 | GTEX | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |